Elicio Therapeutics (ELTX) Return on Capital Employed (2021 - 2026)
Elicio Therapeutics' (ELTX) quarterly Return on Capital Employed came in at 220.46% in Q1 2026, up 5082.0% YoY from 4.25% in Q1 2025, and down 10.85% on a QoQ basis from 198.88% in Q4 2025.
Elicio Therapeutics (ELTX) Return on Capital Employed (2021 - 2026) Analysis & Trends
Elicio Therapeutics (ELTX) has 6 years of Return on Capital Employed data on file, last reported at 220.46% in Q1 2026.
- Quarterly Return on Capital Employed rose 5082.0% year-over-year to 220.46% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 220.46% (up 5082.0% YoY) and the FY2025 annual result came in at 199.44%, up 7930.0% from the prior year.
- Return on Capital Employed retreated to 220.46% in Q1 2026, from 198.88% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 20.48% in Q3 2022 to a low of 329.83% in Q2 2024.
- A 5-year average of 162.13% and a median of 189.13% in 2025 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2024 — Return on Capital Employed tumbled 24473 bps — and 2025, when it jumped 9398 bps.
- Tracing ELTX's Return on Capital Employed over 5 years: stood at 92.39% in 2022, then sank by 100 bps to 185.1% in 2023, then slipped by 12 bps to 206.73% in 2024, then gained by 4 bps to 198.88% in 2025, then dropped by 11 bps to 220.46% in 2026.
- The last three Return on Capital Employed figures came in at 220.46% (Q1 2026), 198.88% (Q4 2025), and 189.13% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.71 Bn | 131.86 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 86.87 Bn | 78.87 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 65.40 Bn | 60.22 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.36 Bn | 54.22 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.91 Bn | 28.60 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.17 Bn | 9.78 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 7.88% |
| 10 | Elicio Therapeutics | 59.08 Mn | 35.58 Mn | - | -212.93% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -212.93% |
| Mar 31, 2026 | -220.46% |
| Dec 31, 2025 | -198.88% |
| Sep 30, 2025 | -189.13% |
| Jun 30, 2025 | -235.85% |
| Mar 31, 2025 | -271.28% |
| Dec 31, 2024 | -206.73% |
| Sep 30, 2024 | -226.61% |
| Jun 30, 2024 | -329.83% |
| Mar 31, 2024 | -192.23% |
| Dec 31, 2023 | -185.10% |
| Sep 30, 2023 | -141.62% |
| Jun 30, 2023 | -85.10% |
| Mar 31, 2023 | -85.37% |
| Dec 31, 2022 | -92.39% |
| Sep 30, 2022 | -20.48% |
| Jun 30, 2022 | -32.00% |
| Mar 31, 2022 | -43.12% |
| Dec 31, 2021 | -42.76% |
| Sep 30, 2021 | -67.99% |